Publicaciones en colaboración con investigadores/as de Queen Mary University of London (2)

2017

  1. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis

    Multiple Sclerosis, Vol. 23, Núm. 10, pp. 1367-1376

2009

  1. Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

    Multiple Sclerosis, Vol. 15, Núm. 2, pp. 219-228